Loading...
ROCO
4186
Market cap27mUSD
Jul 09, Last price  
9.91TWD
1D
-1.88%
1Q
-1.39%
Jan 2017
-59.75%
IPO
-82.77%
Name

Taiwan Advance Bio-Pharmaceutical Inc

Chart & Performance

D1W1MN
ROCO:4186 chart
P/E
31.80
P/S
2.44
EPS
0.31
Div Yield, %
Shrs. gr., 5y
2.12%
Rev. gr., 5y
9.14%
Revenues
365m
+3.00%
205,802,000235,574,000243,363,000318,237,000315,984,000354,173,000364,790,000
Net income
28m
+22.61%
-174,667,000-86,391,000-118,525,0003,170,000-10,682,00022,875,00028,047,000
CFO
51m
+506.93%
-150,752,000-50,325,000-48,082,000-20,593,00012,607,0008,327,00050,539,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Taiwan Advance Bio-Pharmaceutical Inc. is a biotechnology enterprise with a substantial international presence, conducting operations across numerous countries such as China, Germany, the USA, Italy, Malaysia, Vietnam, Thailand, Indonesia, Japan, Korea, and Pakistan, in addition to other global markets. Founded in 1989 and headquartered in New Taipei City, Taiwan, the company delivers a comprehensive array of products and services. Its offerings encompass diagnostic kits for ensuring food safety, alongside tailored customization services for ELISA, rapid, and chemical test kits, and expert consultation for setting up food safety laboratories. The firm also specializes in manufacturing both monoclonal and polyclonal antibody products. Furthermore, its portfolio includes rapid screening tests for illicit substances. It provides essential cell banking services for the secure preservation of both newborn and adult stem cells. The company also operates a dedicated drug testing facility, performing analyses on urine and hair samples to detect and identify drug abuse.
IPO date
Nov 27, 2012
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT